Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
-
M. Rossini
|
maurizio.rossini@univr.it
Rheumatology Unit, University of Verona, Italy.
- O Viapiana Rheumatology Unit, University of Verona, Italy.
- G. Orsolini Rheumatology Unit, University of Verona, Italy.
- E. Fracassi Rheumatology Unit, University of Verona, Italy.
- L. Idolazzi Rheumatology Unit, University of Verona, Italy.
- D. Gatti Rheumatology Unit, University of Verona, Italy.
- S. Adami Rheumatology Unit, University of Verona, Italy.
- M. Govoni Rheumatology Unit, University of Ferrara, Italy.
Abstract
Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
Downloads
Download data is not yet available.
Published
2015-03-31
Keywords:
Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.
Statistics
- Abstract views: 1740
- PDF: 1781
How to Cite
Rossini, M., Viapiana, O., Orsolini, G., Fracassi, E., Idolazzi, L., Gatti, D., Adami, S., & Govoni, M. (2015). Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo, 66(4), 285-303. https://doi.org/10.4081/reumatismo.2014.799
Copyright (c) 2015 M. Rossini, O Viapiana, G. Orsolini, E. Fracassi, L. Idolazzi, D. Gatti, S. Adami, M. Govoni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
